Key result
Beta blockers show potential therapeutic value in managing established septic shock and critical illness.
Why the study?
The role of beta blockers in patients with established septic shock and the adrenergic system in sepsis requires comprehensive review to evaluate potential therapeutic benefits.
Does the use of beta blockers improve outcomes in patients with septic shock?
Does the use of beta blockers improve outcomes in patients with septic shock?
This review explores the rationale and current evidence for using beta blockers, such as esmolol, in the management of septic shock.
Esmolol may improve outcomes in septic shock; leaves open need for RCTs before practice change.
Beta blockers are some of the most studied drugs in the pharmacopoeia. They are already widely used in medicine for treating hypertension, chronic heart failure, tachyarrhythmias, and tremor. Whilst their use in the immediate perioperative patient has been questioned, the use of esmolol in the patients with established septic shock has been recently reported to have favourable outcomes. In this paper, we review the role of the adrenergic system in sepsis and the evidence for the use of beta stimulation and beta blockers from animal models to critically ill patients.
No takes yet. Share an insight, caveat, or question.
Pemberton et al. (2015) conducted a review in Sepsis and septic shock. Beta blockers was evaluated. Beta blockers, including esmolol, are reviewed for their potential therapeutic role and evidence in managing patients with established septic shock and critical illness.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: